CNS Pharmaceuticals (CNSP) has issued an update.
At the Annual Meeting held on April 30, 2024, stockholders of the Company made key decisions impacting the future of the stock. They approved a significant increase of authorized common stock shares from 75 million to 300 million and elected six directors to serve until the next annual meeting. Additionally, they ratified the appointment of an independent accounting firm, authorized a potential reverse stock split, and approved amendments to the equity plan and the repricing and extension of certain warrants. These strategic moves show the company’s proactive steps to adapt and grow, signaling potential shifts in the company’s financial strategy and governance.
For a thorough assessment of CNSP stock, go to TipRanks’ Stock Analysis page.
